Experimental drug tested for deadly skin cancer in rare disease patients
NCT ID NCT03786237
Summary
This small, early-stage study tested an experimental cancer drug called rigosertib in adults with a rare, severe skin condition (RDEB) who had developed an aggressive, hard-to-treat skin cancer. The main goals were to see if the drug could shrink the cancer and to check how safe it was for these patients. Researchers also wanted to understand how the drug worked against the cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EB House Austria/Dept. of Dermatology University Hospital
Salzburg, Salzburg, 5020, Austria
Conditions
Explore the condition pages connected to this study.